The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy

被引：3

作者：

Dong, Heng ^{[1
,2
,3
]}

Zhang, Zhengguo ^{[1
,2
,3
]}

Ni, Mengjie ^{[1
,2
,3
]}

Xu, Xiaoyun ^{[1
,2
,3
]}

Luo, Yifeng ^{[1
,2
,3
]}

Wang, Yaru ^{[1
,2
,3
]}

Zhang, Haiyun ^{[1
,2
,3
]}

Chen, Jianxiang ^{[1
,2
,3
,4
]}

机构：

[1] Hangzhou Normal Univ, Sch Pharm, Affiliated Hosp, Hangzhou 311121, Peoples R China

[2] Hangzhou Normal Univ, Affiliated Hosp, Dept Hepatol, Hangzhou 311121, Peoples R China

[3] Hangzhou Normal Univ, Collaborat Innovat Ctr Tradit Chinese Med, Key Lab Elemene Class Anticanc Chinese Med, Engn Lab Dev & Applicat Tradit Chinese Med, Hangzhou 311121, Zhejiang, Peoples R China

[4] Natl Canc Ctr, Div Cellular & Mol Res, Lab Canc Genom, Singapore 169610, Singapore

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2024年 / 25卷 / 10期

基金：

中国国家自然科学基金;

关键词：

Hepatocellular carcinoma; Immunotherapy; Targeted drugs; Combination therapy; SQUAMOUS-CELL CARCINOMA; IMMUNE CHECKPOINT INHIBITORS; OPEN-LABEL; 1ST-LINE TREATMENT; SINGLE-ARM; LIVER-CANCER; TUMOR-GROWTH; DOUBLE-BLIND; LUNG-CANCER; PHASE-II;

D O I：

10.1007/s11864-024-01246-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is a common type of tumor worldwide. The development of systemic treatment of advanced HCC has remained stagnant for a considerable period. During the last years, a series of new treatment regimens based on the combination of immunotherapeutic drugs and targeted drugs have been gradually developed, increased the objective response rate (ORR), overall survival (OS), and progression free survival (PFS) of HCC patients. Among the different combination therapy groups, atezolizumab plus bevacizumab and sintilimab plus IBI-305 seem to have unique advantages, while head-to-head comparisons are still needed. A comprehensive understanding of the developments, the ongoing clinical trials and the mechanisms of combination of immunotherapy and targeted therapy might lead to the development of new combination strategies and solving current challenges such as the molecular biomarkers, the clinical administration order of drugs and the second-line treatments after combination therapy.

引用

页码：1239 / 1256

页数：18

共 143 条

[61] Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial [J].

Llovet, Josep M. ;

Kudo, Masatoshi ;

Merle, Philippe ;

Meyer, Tim ;

Qin, Shukui ;

Ikeda, Masafumi ;

Xu, Ruocai ;

Edeline, Julien ;

Ryoo, Baek-Yeol ;

Ren, Zhenggang ;

Masi, Gianluca ;

Kwiatkowski, Mariusz ;

Lim, Ho Yeong ;

Kim, Jee Hyun ;

Breder, Valeriy ;

Kumada, Hiromitsu ;

Cheng, Ann-Lii ;

Galle, Peter R. ;

Kaneko, Shuichi ;

Wang, Anran ;

Mody, Kalgi ;

Dutcus, Corina ;

Dubrovsky, Leonid ;

Siegel, Abby B. ;

Finn, Richard S. .

LANCET ONCOLOGY, 2023, 24 (12) :1399-1410

[62] Molecular pathogenesis and systemic therapies for hepatocellular carcinoma [J].

Llovet, Josep M. ;

Pinyol, Roser ;

Kelley, Robin K. ;

El-Khoueiry, Anthony ;

Reeves, Helen L. ;

Wang, Xin Wei ;

Gores, Gregory J. ;

Villanueva, Augusto .

NATURE CANCER, 2022, 3 (04) :386-401

[63] Immunotherapies for hepatocellular carcinoma [J].

Llovet, Josep M. ;

Castet, Florian ;

Heikenwalder, Mathias ;

Maini, Mala K. ;

Mazzaferro, Vincenzo ;

Pinato, David J. ;

Pikarsky, Eli ;

Zhu, Andrew X. ;

Finn, Richard S. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (03) :151-172

[64] Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma [J].

Llovet, Josep M. ;

De Baere, Thierry ;

Kulik, Laura ;

Haber, Philipp K. ;

Greten, Tim F. ;

Meyer, Tim ;

Lencioni, Riccardo .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (05) :293-313

[65] Combine and conquer: challenges for targeted therapy combinations in early phase trials [J].

Lopez, Juanita S. ;

Banerji, Udai .

NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (01) :57-66

[66] Sintilimab plus chemotherapy for patients with EGFR- mutated non-squamous non-small-cell lung cancer with disease progression after EGFRtyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double- blind, randomised, placebo-controlled, phase 3 trial [J].

Lu, Shun ;

Wu, Lin ;

Jian, Hong ;

Cheng, Ying ;

Wang, Qiming ;

Fang, Jian ;

Wang, Ziping ;

Hu, Yanping ;

Han, Liang ;

Sun, Meili ;

Miao, Liyun ;

Ding, Cuimin ;

Cui, Jiuwei ;

Wang, Ke ;

Li, Baolan ;

Li, Xingya ;

Ye, Feng ;

Liu, Anwen ;

Pan, Yueyin ;

Cang, Shundong ;

Zhou, Hui ;

Sun, Xing ;

Shen, Yuping ;

Wang, Shuyan ;

Zhang, Wen ;

He, Yue .

LANCET RESPIRATORY MEDICINE, 2023, 11 (07) :624-636

[67] Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial [J].

Lu, Zhihao ;

Wang, Junye ;

Shu, Yongqian ;

Liu, Lianke ;

Kong, Li ;

Yang, Lei ;

Wang, Buhai ;

Sun, Guogui ;

Ji, Yinghua ;

Cao, Guochun ;

Liu, Hu ;

Cui, Tongjian ;

Li, Na ;

Qiu, Wensheng ;

Li, Gaofeng ;

Hou, Xinfang ;

Luo, Hui ;

Xue, Liying ;

Zhang, Yanqiao ;

Yue, Wenbin ;

Liu, Zheng ;

Wang, Xiuwen ;

Gao, Shegan ;

Pan, Yueyin ;

Galais, Marie-Pierre ;

Zaanan, Aziz ;

Ma, Zhuo ;

Li, Haoyu ;

Wang, Yan ;

Shen, Lin .

BMJ-BRITISH MEDICAL JOURNAL, 2022, 377

[68] Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial [J].

Luke, Jason J. ;

Rutkowski, Piotr ;

Queirolo, Paola ;

Del Vecchio, Michele ;

Mackiewicz, Jacek ;

Chiarion-Sileni, Vanna ;

de la Cruz-Merino, Luis ;

Khattak, Muhammad A. ;

Schadendorf, Dirk ;

Long, Georgina, V ;

Ascierto, Paolo A. ;

Mandala, Mario ;

De Galitiis, Federica ;

Haydon, Andrew ;

Dummer, Reinhard ;

Grob, Jean-Jacques ;

Robert, Caroline ;

Carlino, Matteo S. ;

Mohr, Peter ;

Poklepovic, Andrew ;

Sondak, Vernon K. ;

Scolyer, Richard A. ;

Kirkwood, John M. ;

Chen, Ke ;

Diede, Scott J. ;

Ahsan, Sama ;

Ibrahim, Nageatte ;

Eggermont, Alexander M. M. .

LANCET, 2022, 399 (10336) :1718-1729

[69] Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial [J].

Luo, Huiyan ;

Lu, Jin ;

Bai, Yuxian ;

Mao, Teng ;

Wang, Jun ;

Fan, Qingxia ;

Zhang, Yiping ;

Zhao, Kuaile ;

Chen, Zhendong ;

Gao, Shegan ;

Li, Jiancheng ;

Fu, Zhichao ;

Gu, Kangsheng ;

Liu, Zhihua ;

Wu, Lin ;

Zhang, Xiaodong ;

Feng, Jifeng ;

Niu, Zuoxing ;

Ba, Yi ;

Zhang, Helong ;

Liu, Ying ;

Zhang, Li ;

Min, Xuhong ;

Huang, Jing ;

Cheng, Ying ;

Wang, Dong ;

Shen, Yu ;

Yang, Qing ;

Zou, Jianjun ;

Xu, Rui-Hua .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (10) :916-925

[70] Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial [J].

Ma, L. ;

Zhang, Y. ;

Fang, Y. ;

Hao, C. ;

Fan, Q. ;

Jiang, D. ;

Lu, L. ;

Su, F. ;

Yang, C. ;

Liu, Z. ;

Tian, J. ;

Sun, X. ;

Sun, S. ;

Cheng, Y. .

ANNALS OF ONCOLOGY, 2023, 34 :S599-S600

← 2 3 4 5 6 7 8 9 10 11 →